Japan-based GNI Group Co., Ltd. (TSE: 2160) has agreed to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by Blackstone, valuing the target at approximately JPY 44.8 billion (around USD 279.4 million), in a transaction that substantially reweights GNI Group's revenue base toward Japan's domestic specialty pharmaceutical market. The deal gives GNI Group control of an established commercial infrastructure in pain management and rheumatology, accelerating its stated strategy of building a cross-Pacific biopharmaceutical platform spanning Japan, China, and the US.
The transaction is structured as a full share purchase, with Ayumi Pharmaceutical Holdings becoming a wholly owned subsidiary of GNI Group upon closing. The total consideration is approximately JPY 44.8 billion; a cash-versus-equity breakdown was not disclosed. Ayumi reported revenue of approximately JPY 38.5 billion and operating profit of approximately JPY 6.2 billion for the fiscal year ended March 2026. GNI Group projects combined fiscal 2026 revenue of approximately JPY 65.2 billion following close. No milestone payments, royalties, or contingent value rights are applicable to this structure. Closing conditions were not detailed in the announcement.
Ayumi's commercial value centers on Calonal (acetaminophen), which holds more than 80% of Japan's domestic acetaminophen market, alongside a broader portfolio in rheumatology and orthopedics distributed through a nationwide network reaching healthcare institutions across Japan. For GNI Group, the acquisition provides a ready-made channel to introduce biosimilars and internally developed pipeline assets into Japan, a market where domestic distribution relationships are a material barrier to entry for foreign or cross-border operators.